{
  "metadata": {
    "Author": [
      "Dana Ben-Ami Shor",
      "Miri Blank",
      "Sandra Reuter",
      "Torsten Matthias",
      "Inbal Beiglass",
      "Alexander Volkov",
      "Iris Barshack",
      "Yehuda Shoenfeld"
    ],
    "Content-Type": "application/pdf",
    "Creation-Date": "2014-10-20T06:54:46Z",
    "CrossMarkDomains[1]": "sciencedirect.com",
    "CrossMarkDomains[2]": "elsevier.com",
    "CrossmarkDomainExclusive": "true",
    "CrossmarkMajorVersionDate": "2010-04-23",
    "ElsevierWebPDFSpecifications": "6.4",
    "Last-Modified": "2014-10-20T06:55:15Z",
    "Last-Save-Date": "2014-10-20T06:55:15Z",
    "X-Parsed-By": [
      "org.apache.tika.parser.DefaultParser",
      "org.apache.tika.parser.pdf.PDFParser"
    ],
    "X-TIKA:content_handler": "ToTextContentHandler",
    "X-TIKA:embedded_depth": "0",
    "X-TIKA:parse_time_millis": "131",
    "access_permission:assemble_document": "true",
    "access_permission:can_modify": "true",
    "access_permission:can_print": "true",
    "access_permission:can_print_degraded": "true",
    "access_permission:extract_content": "true",
    "access_permission:extract_for_accessibility": "true",
    "access_permission:fill_in_form": "true",
    "access_permission:modify_annotations": "true",
    "cp:subject": "Journal of Autoimmunity, 54 (2014) 118-126. doi:10.1016/j.jaut.2014.02.013",
    "created": "2014-10-20T06:54:46Z",
    "creator": [
      "Dana Ben-Ami Shor",
      "Miri Blank",
      "Sandra Reuter",
      "Torsten Matthias",
      "Inbal Beiglass",
      "Alexander Volkov",
      "Iris Barshack",
      "Yehuda Shoenfeld"
    ],
    "date": "2014-10-20T06:55:15Z",
    "dc:creator": [
      "Dana Ben-Ami Shor",
      "Miri Blank",
      "Sandra Reuter",
      "Torsten Matthias",
      "Inbal Beiglass",
      "Alexander Volkov",
      "Iris Barshack",
      "Yehuda Shoenfeld"
    ],
    "dc:description": "Journal of Autoimmunity, 54 (2014) 118-126. doi:10.1016/j.jaut.2014.02.013",
    "dc:format": "application/pdf; version=1.4",
    "dc:title": "Anti-ribosomal-P antibodies accelerate lupus glomerulonephritis and induce lupus nephritis in naIve mice",
    "dcterms:created": "2014-10-20T06:54:46Z",
    "dcterms:modified": "2014-10-20T06:55:15Z",
    "description": "Journal of Autoimmunity, 54 (2014) 118-126. doi:10.1016/j.jaut.2014.02.013",
    "doi": "10.1016/j.jaut.2014.02.013",
    "meta:author": [
      "Dana Ben-Ami Shor",
      "Miri Blank",
      "Sandra Reuter",
      "Torsten Matthias",
      "Inbal Beiglass",
      "Alexander Volkov",
      "Iris Barshack",
      "Yehuda Shoenfeld"
    ],
    "meta:creation-date": "2014-10-20T06:54:46Z",
    "meta:save-date": "2014-10-20T06:55:15Z",
    "modified": "2014-10-20T06:55:15Z",
    "pdf:PDFVersion": "1.4",
    "pdf:charsPerPage": [
      "3972",
      "6350",
      "3737",
      "4986",
      "3648",
      "3577",
      "3755",
      "4913",
      "5358",
      "118",
      "1597"
    ],
    "pdf:docinfo:created": "2014-10-20T06:54:46Z",
    "pdf:docinfo:creator": "Dana Ben-Ami Shor",
    "pdf:docinfo:creator_tool": "Elsevier",
    "pdf:docinfo:custom:CrossMarkDomains[1]": "sciencedirect.com",
    "pdf:docinfo:custom:CrossMarkDomains[2]": "elsevier.com",
    "pdf:docinfo:custom:CrossmarkDomainExclusive": "true",
    "pdf:docinfo:custom:CrossmarkMajorVersionDate": "2010-04-23",
    "pdf:docinfo:custom:ElsevierWebPDFSpecifications": "6.4",
    "pdf:docinfo:custom:doi": "10.1016/j.jaut.2014.02.013",
    "pdf:docinfo:custom:robots": "noindex",
    "pdf:docinfo:modified": "2014-10-20T06:55:15Z",
    "pdf:docinfo:producer": "Acrobat Distiller 8.1.0 (Windows)",
    "pdf:docinfo:subject": "Journal of Autoimmunity, 54 (2014) 118-126. doi:10.1016/j.jaut.2014.02.013",
    "pdf:docinfo:title": "Anti-ribosomal-P antibodies accelerate lupus glomerulonephritis and induce lupus nephritis in naIve mice",
    "pdf:encrypted": "false",
    "pdf:hasMarkedContent": "false",
    "pdf:hasXFA": "false",
    "pdf:hasXMP": "true",
    "pdf:unmappedUnicodeCharsPerPage": [
      "2",
      "4",
      "2",
      "43",
      "5",
      "2",
      "0",
      "1",
      "0",
      "0",
      "1"
    ],
    "producer": "Acrobat Distiller 8.1.0 (Windows)",
    "resourceName": "b'150.pdf'",
    "robots": "noindex",
    "subject": "Journal of Autoimmunity, 54 (2014) 118-126. doi:10.1016/j.jaut.2014.02.013",
    "title": "Anti-ribosomal-P antibodies accelerate lupus glomerulonephritis and induce lupus nephritis in naIve mice",
    "xmp:CreatorTool": "Elsevier",
    "xmpMM:DocumentID": "uuid:1b0853d8-6cb6-4f61-a15f-5b9827355e43",
    "xmpTPg:NPages": "11"
  },
  "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAnti-ribosomal-P antibodies accelerate lupus glomerulonephritis and induce lupus nephritis in naIve mice\n\n\nlable at ScienceDirect\n\nJournal of Autoimmunity 54 (2014) 118e126\n\ni An update to this article is included at the end\nContents lists avai\nJournal of Autoimmunity\n\njournal homepage: www.elsevier .com/locate/ jaut imm\nAnti-ribosomal-P antibodies accelerate lupus glomerulonephritis and\ninduce lupus nephritis in na\u00efve mice\n\nDana Ben-Ami Shor a,1, Miri Blank a,1, Sandra Reuter b, Torsten Matthias b, Inbal Beiglass a,\nAlexander Volkov c, Iris Barshack c, Yehuda Shoenfeld a,*\na The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Israel\nbAESKU.KIPP Institute, Mikroforum Ring, Wendelsheim, Germany\nc Institute of Pathology, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Israel\na r t i c l e i n f o\n\nArticle history:\nReceived 1 May 2013\nReceived in revised form\n18 February 2014\nAccepted 26 February 2014\nAvailable online 21 March 2014\n\nKeywords:\nAnti-ribosomal-P\nSystemic lupus erythematosus\nGlomerulonephritis\n* Corresponding author. Zabludowicz Center for A\nMedical Center, Tel-Hashomer 52621, Israel. Tel.: \u00fe97\n\nE-mail addresses: mblank@post.tau.ac.il (M. Bl\n(Y. Shoenfeld).\n\n1 The first two authors equally contributed to the p\n\nhttp://dx.doi.org/10.1016/j.jaut.2014.02.013\n0896-8411/\ufffd 2014 Elsevier Ltd. All rights reserved.\na b s t r a c t\n\nBackground: Lupus nephritis is known to be associated with several antibodies including autoantibodies\nthat target the DNA, C1q and histone, a-actinin, and the nucleosome. In addition, circulating anti-\nphosphoribosomal protein antibodies (anti-Ribos.P) were found to be associated with lupus nephritis.\nStudy objective: We have assessed the direct role of anti-Ribos.P in the development of glomerulone-\nphritis in-vitro and in animal models.\nStudy design: NZBxW/F1 lupus prone mice were immunized with recombinant Ribos.P0 (rRibos.P).\nEvaluation of renal disease included mice evaluation for proteinuria and histologic analysis of the kidneys.\nAnti-Ribos.P monoclonal Ab was prepared from the rRibos.P immunized NZBxW/F1 mice by hybridoma\ntechnology. MAPKs expression was analyzed by MAPKs protein array and confirmed by real-time PCR and\nwestern blot. To elucidate whether anti-Ribos.P induce glomerulonephritis, na\u00efve C3H mice were\nimmunized with recombinant rRibos.P and the glomerulonephritis was followed up as described above.\nResults: The immunized NZBxW/F1 lupus prone mice developed anti-Ribos.P which was cross reactive\nwith Sm and not dsDNA. The mice developed accelerated glomerulonephritis manifested by early pro-\nteinuria and immunoglobulin deposites in the mesangium of the kidneys. Anti-Ribos.P deposited in the\nglomerular mesangium were eluted from the kidney. The Ribos.P immunized na\u00efve C3H/Hen mice\ndeveloped glomerulonephritis manifested by circulating autoantibodies directed to Ribos.P, dsDNA and\nSm. The anti Ribos.P were cross reactive with Sm but not with dsDNA, and were deposited in the\nglomeruli. Interestingly these mice developed alopecia. In vitro. Primary mesangial cells exposed to\nmouse anti-Ribos.P mAb originated from the immunized lupus mice and to human anti-Ribos.P Abs,\ninduced activation of mesangial cells via p38a, JNK, AKT and HSP27 MAPKs expression pathway.\nConclusions: Our data show for the first time that anti-Ribos.P are nephritogenic autoantibodies, as\nillustrated by in-vitro and in-vivo experiments: a) They accelerate the development of glomerulone-\nphritis in lupus prone mice; b) They induce nephritis in na\u00efve mice. c) Anti-Ribos.P Abs trigger MAPKs\nexpression in primary mesangial cells. These data contribute a direct mechanistic link between anti-\nRibos.P and nephritis in lupus mice.\n\n\ufffd 2014 Elsevier Ltd. All rights reserved.\n1. Introduction\n\nAmong the wide spectrum of clinical manifestations in systemic\nlupus erythematosus (SLE), nephritis occurs in 40e60% of SLE\nutoimmune Diseases, Sheba\n2 3 5308070.\nank), shoenfel@post.tau.ac.il\n\naper.\npatients. Because lupus nephritis progress into renal failure, it is a\nprincipal cause of death among SLE patients [1]. Glomerulone-\nphritis classification in SLE according to the World Health\nOrganization (WHO) comprises six histological classes. The Inter-\nnational Society of Nephrology (ISN) and the Renal Pathology So-\nciety (RPS), have published a newer, similar classification with the\naddition of \u201ca\u201d for active and \u201cc\u201d for chronic changes. The advantage\nof the ISN/RPS classification is that it supplies the information\nregarding the potential reversibility of the disease [2]. Renal fibrosis\nand subsequent renal failure are caused by recurrent inflammation\n\nDelta:1_given name\nDelta:1_surname\nDelta:1_given name\nDelta:1_surname\nDelta:1_given name\nDelta:1_surname\nDelta:1_given name\nDelta:1_surname\nmailto:mblank@post.tau.ac.il\nmailto:shoenfel@post.tau.ac.il\nhttp://crossmark.crossref.org/dialog/?doi=10.1016/j.jaut.2014.02.013&domain=pdf\nwww.sciencedirect.com/science/journal/08968411\nwww.elsevier.com/locate/jautimm\nhttp://dx.doi.org/10.1016/j.jaut.2014.02.013\nhttp://dx.doi.org/10.1016/j.jaut.2014.02.013\nhttp://dx.doi.org/10.1016/j.jaut.2014.02.013\n\n\nD. Ben-Ami Shor et al. / Journal of Autoimmunity 54 (2014) 118e126 119\nand augmentation of local inflammatory responses, including the\ndeposition of immunoglobulins within the glomerular and tubular\nbasement membranes [3]. The lupus nephritis enigma for several\ndecades. In the late 1960s, using immunofluorescence, Koffler et al.\nshowed that immune complexes are involved in lupus nephritis\npathogenesis and they found anti-dsDNA autoantibodies in the\nkidneys of patients who presented with lupus nephritis [4].\n\nLupus nephritis is known to be associated with several anti-\nbodies, including autoantibodies that target the DNA (4), C1q and\nhistone, a-actinin [5e7], and the nucleosome [8]. dsDNA reactive\nantibodies are believed to play a critical role in the pathogenesis of\nlupus nephritis through three main mechanisms: a) tissue damage\ndue to the in-vitro mesangial cell penetration of anti-dsDNA anti-\nbodies which cross react with kidney antigens; b) the formation of\nanti-dsDNA antibodies immune complexes with DNA/nucleosomes,\nwhich are released from apoptotic cells; and c) in situ formation of\nanti-dsDNA antibodies and nucleosomes immune complexes [6,9].\nAdditionally, in a more recent study, researchers were able to show\nthat glomerular inflammation induction is strongly related to the\ndirect binding of anti-dsDNA antibodies to antigens in the glomer-\nular basement membrane or mesangial matrix [10].\n\nIn 1965, Sturgill and Carpenter [11] were the first to identify\nanti-Ribos.P Abs which target the intracellular ribosomal phos-\nphoprotein. Anti-Ribos.P Abs bind to three main ribosomal pro-\nteins: P0, P1 and P2 (38 kd, 19 kd and 17 kd), respectively [12].\nThese antibodies targets mainly the22 amino acids region, which is\nlocated at the carboxyl terminal end (C-22) of the ribosomal S60\nsubunit, This complex includes two copies each of P1 and P2 and a\nsingle copy of P0. The interaction of the pentameric complex with\nthe 28S rRNA molecule, creates the GTPase domain, which in turn\nplays a part in the elongation process of protein translation [13].\n\nAmong lupus patients, the reported prevalence of anti-Ribos.P\nAbs is 10e40%, with a high specificity of the Abs with neuropsy-\nchiatric SLE (NPSLE) [14,15]. Correlations between anti-Ribos.P Abs\nand neuropsychiatric clinical expressions include psychosis,\ndelirium, cognitive impairment, mood disorders, and anxiety [16].\nAdditionally, intracerebroventricular administration of human\nanti-Ribos.P induced depression in na\u00efve mice [17].\n\nA link between anti-Ribos.P autoantibodies and nephritis,\nhepatitis and skin manifestations in lupus patients was reported\npreviously [18,19]. Anti-Ribos.P Abs have high specificity for SLE\n[20] with clear correlation to SLE disease activity. Moreover, the\npresence of these Abs was more prevalent in patients in which\nSLE appeared during adolescence compared to patients in whom\nthe disease developed at a later age [21].\n\nMeroni PL et al. first reported the association between anti-\nRibos.P Abs and renal injury in patients with lupus in 1984 [22]\nReichlin\u2019s group showed that in patients demonstrating anti-\nRibos.P Abs, lupus nephritis was significantly more prevalent than\nin those who were negative for these Abs [23]. This group also\ndemonstrated anti-Ribos.P Abs titer fluctuations, based on exacer-\nbation and remission intervals of the disease [24]. Several another\nstudies further showed that the simultaneous expression of anti-\ndsDNA Abs and anti-Ribos.P strongly correlate with lupus\nnephritis [21,25,26]. Furthermore, Bonfa et al. [27] proposed that\nanti-Ribos-P Abs may have a potential serologic marker for mem-\nbranous glomerulonephritis (class V) in SLE patients, while de\nMacedo et al. [28] suggested that during nephritis flares, in the\nabsence of anti-dsDNA, anti-Ribos.P Abs predict a better renal\nprognosis. Another group showed a high (but not significant) co-\npredominance in lupus nephritis class IV and V of anti-dsDNA\nAbs and anti-Ribos.P [29]. However, others showed no correlation\nbetween lupus nephritis and anti-Ribos.P Abs [30,31].\n\nIn our study, we report that anti-Ribos.P accelerate lupus\nnephritis in lupus prone mice and de novo induction of anti-\nRibos.P Abs cause renal injury and lupus skin manifestations.\nWe demonstrate the ability of anti-Ribos.P mAbs to bind\nmesangial cells and induce MAPKs, which can serve as an\nimportant mechanism for mediating renal tissue injury.\n\n2. Materials and methods\n\n2.1. Antibodies\n\nThe following Abs were used in these studies:\nHuman anti-Ribos.P IgG Abs were affinity purified on a\n\nribosomal-P column from sera originated from a patient with\nNPSLE accompanied with nephritis as previously described [32].\nControl human IgG (h.cIgG) or mouse Ig1 were of commercial\norigin (m.cIgG (Jackson ImmunoResearch Laboratories, Inc., West\nGrove, PA, USA)).\n\nGeneration of mouse anti-Ribos. mAbs: The mouse anti-Ribos.P\nmAbs were prepared as previously described by us (33). Spleen\ncells were isolated form three NZBxW/F1 rRibos.P immunized, 3\nmonths after the boost. The splenocytes were fusedwith themouse\nplasmacytoma cell line \ufffd63.653 at a ratio of 10:1 in the presence of\nPEG (polyethylene glycol) 1500, and seeded in 96 wells in HAT\nmedium using standard techniques as previously described by us\n[33]. The positive clones were subjected three times to a limiting\ndilution procedure. The anti-Ribos.P specific mAb detection was\nperformed by screening culture fluids on Ribos.P coated plates\n(AESKU) by ELISA, and on ELISA plates coated with synthetic pep-\ntide RIBOSPEP 50 mg/ml in PBS overnight at 4 \ufffdC. Scrambled\nRIBOSPEP peptide coated ELISA plates were used as control. The\nplates were blocked with 3%BSA in PBS 1 h at 37C. Following\n4 h incubation time with the tested culture fluid, the immuno-\nglobulin binding was probed with a goat-anti-mouse IgG-alkaline-\nphosphatase and later the appropriate substrate was added. Data\nwere read at OD 405 nm ref.650 nm. The selected mouse anti-\nRibos.P mAb M7/3 IgG1 bound specifically to Ribos.P in a dose\ndependent manner and the RIBOSPEP synthetic peptide (carboxy-\nterminal 22-amino acid of the ribosome.P as described below) was\nable to inhibit M7/3 mAb binding to Ribos.P by 97 \ufffd 8% at a con-\ncentration of 12 mg/ml in comparison to 3 \ufffd 2% in the presence of\nscRIBOPEP, P < 0.001 (Fig. 1).Commercial mouse IgG1 isotype\n(cmIgG) (Jackson) was used as negative control.\n\nGeneration of mouse anti-anti-Ribos. mAbs: C3H mice were\nimmunized with Ribos.P in CFA, The mice were boosted twice with\n2 weeks intervals with Ribos.P in incomplete Freuds adjuvant. Two\nweeks later the mice developed high titers of anti-anti-Ribos.P. IgG.\nThe sera was loaded on anti-Ribos.P mAb column and the eluted\nIgG was anti-anti-Ribos.P IgG.\n\n2.2. Synthetic peptides\n\nThe synthetic peptide is composed of the carboxy-terminal 22-\namino acid of the ribosome-P protein and has the following\nsequence: Lys-Lys-Glu-Glu-Lys-Lys-Glu-Glu-Ser-Glu-Glu-Glu-\nAsp-Glu-Asp-Met-Gly-Phe-Gly-Phe-Leu-Phe-OH named RIBO-\nSPEP. The control scrambled form of this peptide is: Met-Lys-Glu-\nLys-Glu-Glu-Ser-Lys-Phe-Asp-Gly-Glu-Asp-Glu-Glu-Leu-Phe -Glu-\nPhe-Lys-Gly-Glu-OH. The peptides were synthesized by GL-\nBiochem, Shanghai Ltd, Shanghai, China.\n\n2.3. Immunization\n\nFemale NZBxW/F1 lupus prone mice at 12 weeks of age were\nobtained from The Harlan Laboratories (Bicester, UK). Female C3H/\nHen mice at 12 weeks of age were purchased from Harlan Labo-\nratories (Rehovot, Israel). Mice were handled under protocols\n\n\n\nFig. 1. Autoantibodies profile in the sera of rRibos.P0 immunized NZBxW/F1 mice:\n1a: levels of circulating anti-Ribos.P IgG at the age of 20 weeks in comparison to 34\nweeks, when the mice already have proteinuria in NZBxW/F1 rRibos.P immunized\nmice and CFA injected mice. 1b: Example of anti-Ribos.P0 binding by immunoblot. 1c:\nTiters of anti-dsDNA in NZBxW/F1 rRibos.P immunized mice and CFA injected mice, at\nimmunized with 14, 20, 28, 34 weeks of age.\n\nD. Ben-Ami Shor et al. / Journal of Autoimmunity 54 (2014) 118e126120\napproved by the Sheba Medical Center Animal Care and The Israel\nMinistry of Health Committee according to international\nguidelines.\n\nNZBxW/F1 and C3H/Hen mice were immunized with recombi-\nnant ribosomal-P0 (rRibos.P0)(AESKU, Wendelsheim, Germany),\n10 mg/0.1 ml/mouse emulsion in Complete Freunds\u2019 Adjuvant (CFA)\ninto the hind footpads. Three weeks later a booster injection was\ngiven in PBS at the same location. NZBxW/F1 (n \u00bc 20) mice were\nimmunized with rRibos.P at the age of 12 weeks, boosted at the age\nof 15 weeks. Five mice were immunized with CFA and one group of\nNZBxW/F1 mice were not immunized. The C3H/Hen (n \u00bc 20) mice\nwere immunized at the age of 12 weeks using the same protocol\nand boosted at 15 weeks. C3H/Hen mice (n \u00bc 20) were immunized\nwith CFA.\n\n2.4. Detection of autoantibodies in mice sera\n\nMouse anti-dsDNA: Anti-dsDNA Abs binding in the mice sera\nwere detected by home-made ELISA as previously described by us\n[34]. Briefly, mice sera diluted 1:200 were applied to the dsDNA\ncoated ELISA plates, incubated for 60 min at room temperature.\nBound antibodies were probed by using alkaline phosphatase\nconjugated goat anti-mouse IgG (H \u00fe L) (Jackson) diluted 1:5000\nfollowed by appropriate substrate (Sigma, St Louis, MO, USA). Data\nwere read by a Titertrek ELISA reader at 405 nm filter/620 nm\nreference filter.\n\nMouse anti-Ribos.P Abs were evaluated in the mice sera by\nemploying Anti-ribos.P kits (AESKU). Mice sera at a dilution of\n1:200 were added to the dilution buffer for 30 min at room tem-\nperature. The binding was probed with a goat anti-mouse IgG-\nperoxidase (Jackson) at a dilution 1:10,000, followed by an appro-\npriate substrate according to the manufacturer instructions. The\ndata were read at OD of 450 nm.\n\nMouse anti-Sm Abs were evaluated in the mice sera by using\nELISA coated and blocked Sm plates (INOVA, Diagnostic Inc. San-\nDiego, CA, USA) as described above for anti-Ribos.P.\n\nInhibition assays: Mouse anti-dsDNA Abs were affinity purified\nfrom sera of NZBxW/F1 mice and C3H/Hen mice, immunized with\nrRibos.P, on a cellulose column as previously described by us (34).\nInhibition assays were performed using affinity purified anti-\ndsDNA Abs, IgG from NZBxW/F1 mice immunized with Ribos.P,\nafter depletion of anti-dsDNA on a cellulose column, followed by\nprotein affinity purification and anti-Ribos.P mAb, all at 50% bind-\ning to the specific plate. dsDNA, and Ribosomal-P were used as\ninhibitors at different concentrations (5e50 mg/ml), for dsDNA\nbinding and Sm/RNP binding by ELISA.\n\n2.5. Evaluation of renal disease\n\nMice were evaluated for proteinuria using Multistix strips\n(Bayer Diagnostics, Puteau, France). Urine samples were graded 0e\n4\u00fe, corresponding to the following approximate protein concen-\ntrations: 0 \u00bc negative or trace, 30 mg/dl, 100 mg/dl, 300 mg/dl and\n\ufffd2000 mg/dl. Mice with a significant proteinuria (\ufffd300) on two\nconsecutive examinations were designated positive for renal dis-\nease. Severely ill and wasted mice with a significant proteinuria\nwere sacrificed when they appeared moribund. These mice were\nconsidered as dead at the time they were killed and were included\nin the survival evaluation.\n\nHistologic analysis of the kidneys: Mice perfused with PBS were\nparaffin embedded. Five micron sections were stained for H&E. For\ndetection of Ig deposits, paraffin sections (4e5 mm) were incubated\nwith ananti-mouse Fc IgG FITC-conjugated (Jackson). Evaluationwas\nperformed by two pathologists that were blinded to the diagnosis.\n\n2.6. Immunoglobulin elution from the kidneys\n\nLysate from the kidneys were prepared following perfusionwith\nPBS. The kidneys were homogenized with Glycine-HCl O.2M pH2.5.\nThe eluate was dialyzed against PBS. Anti-ribos.P binding was\ndetected by ELISA.\n\n2.7. Preparation of primary mouse mesangial cells (MCs)\n\nMCs from C3H/Hen mice kidneys were isolated according to a\nprotocol described by Deocharan B et al. [7]. The outer cortexes of\n\n\n\nD. Ben-Ami Shor et al. / Journal of Autoimmunity 54 (2014) 118e126 121\n10 kidneys were minced with a razor, and the tissue was forced\nthrough progressively smaller stainless steel sieves (180, 150, and\n90 mm, Sigma). Glomeruli were then caught on a 75-mm sieve,\nwashed twice with PBS, and centrifuged for 5 min at 220 g. The\nwashed glomeruli were treatedwith collagenase for 20min at 24 \ufffdC\nand washed again as above. Cells were plated out in RPMI 1640\nsupplemented with non-essential amino acids, sodium pyruvate,\ninsulin, and 20% FCS, and maintained at 37 \ufffdC/5% CO2. The media\nwas changed every 4 days. After 30 days, the cultures consist of\nvirtually pure MCs.\n\n2.8. MCs Treatments, lysate preparation, immunoblotting and real-\ntime-PCR\n\nMCs derived from C3H mice kidneys, were exposed to human\nanti-Ribos.P Abs, mouse anti-Ribos.P mAbs control human IgG and\ncontrol mouse IgG1 isotype control (20 mg/ml) for 4 h. Subse-\nquently, the cells were lysed in lysis buffer (20 mM TrisHCl (pH 7.5),\n1%SDS, protease inhibitor cocktail, and 0.2 mM PMSF, all the re-\nagents were purchased from Sigma), incubated 30 min at 4 \ufffdC, and\ncentrifuged to remove debris. The protein content of the lysate was\nmeasured using the BCA\ufffd protein assay kit (Thermo Scientific,\nRockford, IL, USA). Phospho-MAPKs membrane arrays (R&D Sys-\ntems Inc, Minneapolis, MN, USA) were exposed to the different\nlysates originated from MCs exposed to anti-Ribos.P Abs and the\nrelevant controls, according to the manufacturer\u2019s protocol [35].\n\nTotal mRNA was isolated using the Qiagen RNA isolation kit\naccording to the manufacturer\u2019s instructions. RNAwas then reverse\ntranscribed into cDNA by MMLV reverse transcriptase. Five micro-\ngrams of total RNA was transcribed to cDNA in a 30-ml reaction\nvolume. For transcript quantification by real-time PCR, the SYBR\nGreen Mix containing Thermo-Start DNA Polymerase (InVitroGene,\nCA, USA) was used according to the manufacturer\u2019s instructions.\ncDNA samples were amplified using specific primers. PCR amplifi-\ncationwas performedwith specific forward and reverse primers for\np38a (forward, 50-58GTGCCCGAGCGTTACCAGACC78-30; reverse,\n50-370CTGTAAGCTTCTGACATTTC351-30), The levels of p38a mRNA\nwere adjusted to the levels of aactin. a5\u2019 e primer (50- TCATG\nAAGTGTGACGTTGACATCCGTA-AAG-30) and 30 e primer (50- CCTAG\nAAGCATTTGCGGTGCACGATGGAGG e 30). aactine primers were as\nTable 1\nPercent inhibition of binding of affinity purified anti-dsDNA, mouse-IgG depleted of anti\n\nELISA\n\nRibos.P Sm\n\nTested Ab: Anti-dsDNA bIgG, anti\ndsDNA\ndepleted\n\nAnti-Ribos.P\nmAb\n\nAnti-dsDNA\n\nInhibitor: dsDNA Ribos.P Ribos.P dsDNA Ribos.P Ribos.P\n\nConcentration mg/ml 50 50 50 50\n\nNZBxW/F1 immunized\nwith Ribos.P\n\n1a 3c 4 98 \ufffd 5 4 \ufffd 2 97 \ufffd 4 15\n2 5 2 95 \ufffd 3 9\n3 4 3 99 \ufffd 7 11\n4 6 5 97 \ufffd 9 14\n5 2 4 98 \ufffd 4 12\n\nC3H/Hen immunized\nwith Ribos.P\n\n1 2 9 96 \ufffd 6 16\n2 6 8 98 \ufffd 4 12\n3 7 10 96 \ufffd 5 9\n4 11 6 99 \ufffd 7 17\n5 8 7 97 \ufffd 9 11\n\nControl IgG inhibition of binding by specific antigen to: Ribos.P e 8 \ufffd 2; Sm e 5 \ufffd 2; ds\na Mouse number from which IgG was purified. Each number composed of IgG affinity\nb IgG fromNZBxW/F1mice immunizedwith Ribos.P, after depletion of anti-dsDNA on a\n\noriginated from NZBxW/F1 mice immunized with Ribos.P.\nc Data are presented as percent of inhibition.\nfollows: forward: 50-cagcctcaagatcatcagca; reverse-30: reverse: 50-\ngtcttctgggtggcagtgat-30; accession number: M33197. Amplification\nwas monitored by real-time PCR analysis using the ABI/Prism 7700\nSequence Detector System (Applied Biosystems).\n\n3. Results\n\n3.1. rRibos.P0 NZBxW/F1 immunized mice developed accelerated\nglomerulonephritis\n\nWe studied the potential of de-novo generated mouse anti-\nRibos.P Abs by immunizing NZBxW/F1 lupus prone mice with\nrRibos.P0, on the development of glomerulonephritis. We analyzed\nthe titers of autoantibodies, proteinuria, immunoglobulin deposi-\ntion in the glomeruli and we eluted mouse anti-Ribos.P0 from the\nkidneys of the rRibos.P0 immunized mice. NZBxW/F1 lupus prone\nmice, immunized with rRibos.P0, developed an earlier glomerulo-\nnephritis than the adjuvant immunized mice week 18e22 in\ncomparison to the adjuvant injected mice which developed\nglomerulonephritis at week 32e34. These mice developed high\ntiters of anti-Ribos.P Abs which remained steadily high until the\ntimewhen the mice developed glomerulonephritis, at the age of 34\nweeks (Fig. 1a), P < 0.001. The data were confirmed by an immu-\nnoblot (Fig. 1b). Whereas the CFA immunized mice, did not develop\nanti-Ribos.P Abs. However, the titers of anti-dsDNA Abs in the sera\nwere elevated in both, in the rRibos.P0 and the CFA immunized\nmice (Fig. 1c). The titers of anti-dsDNA were not affected by the\nimmunization procedure with rRibos.P, p > 0.05, (Fig. 1c).\n\nAs depicted in Table 1, anti-Ribos.P Abs were not cross reactive\nwith dsDNA since anti-dsDNA affinity purified from the sera of\nNZBxW/F1 mice, did not bind Ribos.P ELISA plate and was not\ninhibited by Ribos.P on dsDNA ELISA plate. Moreover, the datawere\nconfirmed by using anti-Ribos.P mAb derived from these mice. The\nanti-Ribos.P mAb binding to Ribos.P was not inhibited by dsDNA\nand no anti-dsDNA binding was observed (Table 1).Interestingly, a\ncross reactivity between Ribos.P and Sm antigen was detected\n(Table 1).Anti-Sm binding was tested by using polyclonal IgG from\nthe lupus mice which were anti-dsDNA depleted, anti-Ribos.P mAb,\nand Ribos.P as inhibitor. The data show that Ribos.P inhibited anti-\nRibos.P binding by 40%. p < 0.004.\n-dsDNA and anti-Ribos.P mAb to dsDNA, Ribos.P and Sm by ELISA.\n\ndsDNA\n\nIgG\nanti-dsDNA\ndepleted\n\nAnti-Ribos.P\nmAb\n\nAnti-dsDNA IgG\nanti-dsDNA\ndepleted\n\nAnti-Ribos.P\nmAb\n\nRibos.P dsDNA Ribos.P dsDNA Ribos.P Ribos.P dsDNA Ribos.P\n\n50 50 50 50 50\n\n45 \ufffd 3 7 \ufffd 2 47 \ufffd 4 97 3 6 \ufffd 1 5 \ufffd 2 3 \ufffd 1\n36 \ufffd 4 99 5 7 \ufffd 1\n54 \ufffd 6 98 6 8 \ufffd 7\n39 \ufffd 4 96 4 9 \ufffd 2\n45 \ufffd 3 95 5 7 \ufffd 3\n49 \ufffd 4 99 6 8 \ufffd 3\n52 \ufffd 5 97 8 9 \ufffd 2\n57 \ufffd 6 98 6 6 \ufffd 2\n46 \ufffd 5 95 9 7 \ufffd 3\n53 \ufffd 5 99 7 8 \ufffd 2\n\nDNA e 11 \ufffd 3.\npurified from sera pooled from 2 mice.\ncellulose column, followed by protein affinity purification. The anti-Ribos.P mAbwas\n\n\n\nPeptide g /ml\n\n0 10 20 30 40 50\n\nnoitibihnI\n%\n\n0\n\n20\n\n40\n\n60\n\n80\n\n100\n\nRIBOPEP\n\nscRIBOPEP\n\n\u03bc\n\nFig. 2. Inhibition assay of mouse anti-Ribos.P mAb binding to Ribos.P by Ribos.P\nspecific peptide RIBOPEP. The inhibitors were RIBOPEP and its scrambled form\nscRIBOPEP. The data are mean \ufffd SD of 3 experiments.\n\nD. Ben-Ami Shor et al. / Journal of Autoimmunity 54 (2014) 118e126122\nGiven that the titers of circulating anti-Ribos.P were elevated in\nthe rRibos.P0 immunized mice, we assessed the deposition of these\nAbs in the kidneys. Mouse anti-Ribos.P IgGAbs were extracted from\nthe kidneys of rRibos.P0 immunized mice. The immunoglobulin\nextracted from the kidneys of the rRibos.P immunized mice in\ncomparison to the adjuvant immunized mice were analyzed for\nanti-Ribos.P binding by ELISA. The data revealed 1.065 \ufffd 0.112 OD\nat 405 nm for the Ig extracted from rRibos.P immunized mice\nkidneys in comparison to 0.213 \ufffd 0.087 for the Ig extracted from\nthe CFA immunized kidneys. Yet, a direct confirmation for the\nnephritogenic activity of anti-Ribos.P in the development of\nglomerulonephritis was needed. Therefore, we have generated a\nmouse anti-Ribos.P0 mAb from the splenocytes of NZBxW/F1 rRi-\nbos.P0 immunized mouse. The anti-Ribos.P0 mAb recognized a\nsynthetic peptide composed of the carboxy-terminal 22-amino acid\nof the ribosome-P protein (RIBOSPEP) by ELISA. As illustrated in\nFig. 2, the RIBOSPEP inhibited the binding of anti-Ribos.P mAb to\nrRibos.P0 by 98.4 \ufffd 7.1% at the concentration of 10 mg/ml, whereas\nFig. 3. A link between anti-Ribos.P Abs and glomerulonephritis in lupus prone mice\nimmunized with rRibos.P and mice immunized with adjuvant (CFA). 3b: Histological ana\nrRibos.P, adjuvant and non-immunized mice, exemplified by H&E staining and immunoglo\nscRIBOSPEP inhibited by only 2.3 \ufffd 1.2, at the same concentration\np < 0.001.\n\nAccelerated proteinuria was discerned in the group of mice\nimmunized with rRibos.P0, as illustrated in Fig. 3a, p < 0.01. The\nrRibos.P0 immunized group of mice, showed a higher percentage of\nmice having >100 mg/dl proteinuria (40% at week 20, 60% at week\n24) in comparison with the CFA immunized mice (1% at week 20\nand 59% at week 24).At the age of 18 weeks (3 weeks after boost\nadministration), Ribos.P0 immunized mice already began to\ndevelop proteinuria whereas the control mice did not (Fig. 3a). As\nshown in Fig. 3b, renal histopathology at week 24 of age, revealed\ntypical findings of focal and diffuse proliferative damage in\nglomerulus shown by H&E staining. Immunofluorescence staining\nillustrate immunoglobulin deposits in the glomeruli with diffuse\npattern of diffuse peripheral deposition (Fig. 3b). Whereas, no\nsignificant immunoglobulin deposition in the glomeruli was\nobserved in the kidneys of adjuvant immunized mice or in the non-\nimmunized mice of the same age.\n\n3.2. Na\u00efve mice immunized with rRibos.P0, developed\nglomerulonephritis and experimental lupus\n\nWe immunized C3H/Hen female mice with rRibos.P0 emulsified\nin CFA as an adjuvant. One-month after booster administration, the\nrRibos.P0 immunized mice developed significantly elevated titers\nof circulating anti-Ribos.P0 Abs (p < 0.001), when compared to\ncontrol CFA immunized mice (Fig. 4a). In addition, the mice\ndeveloped high levels of circulating anti-dsDNA Abs which\nremained constant over the time as depicted in Fig. 4b. Elevated\nanti-Sm Abs were shown in the rRibos.P0 injected mice (Fig. 4c). As\nshown in Table 1, anti-Ribos.P Abs were not cross reactive with\ndsDNA since anti-dsDNA affinity purified from the sera of C3H/Hen\nmice, did not bind Ribos.P and were not inhibited by Ribos.P on\ndsDNA ELISA plate. However, a cross reactivity between anti-\nRibos.P and Sm antigen was illustrated (Table 1). Polyclonal IgG\nanti-dsDNA depleted binding to Sm ELISA plates was inhibited by\nRibos.P (46% up to 57% inhibition), p < 0.01. Clinically, all the rRi-\nbos.P0 injected mice exhibited proteinuria at 4 months after the\nbooster administration (e.g 100 mg/dl) whereas the CFA injected\nmice did not develop proteinuria (0e30 mg/dl). Renal histopa-\nthology at 4 months after boost injection revealed a diffuse\n. 3a: Percent of mice with proteinuria above 100 mg/dl. Comparison between mice\nlyses of kidneys: comparison of glomerulonephritis between mice immunized with\nbulin deposition in the glomeruli by immunofluoresence.\n\n\n\nFig. 4. Autoantibodiesprofile in theseraofna\u00efvemice immunizedwithrRibos.P.4a: Titersof\ncirculatinganti-Ribos.PAbs in theseraofC3H/Henmiceatweeks14, 24, 32weeksafterboost\ninjection.4b: Titers of circulatinganti-dsDNA in theseraofC3H/Henmiceatweeks14, 24, 32\nweeksafterboost injection.4c: Titers of circulatinganti-Sm/RNP in theseraofC3H/Henmice\nat week 32 after boost injection.\n\nD. Ben-Ami Shor et al. / Journal of Autoimmunity 54 (2014) 118e126 123\nproliferative mesangial damage with diffuse peripheral deposition\nby immunofluorescence (Fig. 5a). Furthermore, anti-Ribos.P0 was\neluted from the kidney. Analyses of the immunoglobulins eluted\nfrom the kidneys,showed elevated anti-Ribos.P0 activity by ELISA\n(OD of 0.893 \ufffd 0.078 in comparison to OD of 0.0930 \ufffd 0.03 in the\nlysate of kidneys from the CFA injected mice).\n\nIn addition all the C3H/Hen immunized mice with rRibos.P\ndeveloped alopecia on their face (a well-known skin manifestation\nof lupus), whereas control mice did not (Fig. 5b).\n\n3.3. Anti-Ribos.P activate p38 MAPK in mesangial cells in-vitro\n\nMouse mesangial cell cultures prepared from healthy C3H/Hen\nfemale kidneys. In order to follow the effect of anti-Ribos.P on\nmesangial cells signaling cascade, a lysate from the mesangial cells\nwas introduced to protein MAPKs protein array. The mesangial cell\ncultures were pre-exposed for 24 h to mouse anti-Ribos.P mAb and\nits IgG1 control or to a human anti-Ribos.P IgG and its IgG control.\nAs shown in Fig. 6a, anti-Ribos.P originated either from human\nlupus patient or from a mouse origin, enhanced significantly the\nexpression of phosphorylated p38a P < 0.001 by densitometry and\nHSP27, p < 0.02 in densitometry. Furthermore, as described in\nFig. 6b, the expression of p-p38 was confirmed in the level of mRNA\nby real time PCR, p < 0.004 for human anti-Ribos.P and p < 0.01 for\na mouse anti-rRibos.P in comparison to the relevant control\nimmunoglobulin. The data were confirmed by immunoblot, Fig. 6c.\nThe immunoblot analyses demonstrated that anti-Ribos.P from\nmouse and human origins, as well as anti-dsDNA IgG affinity pu-\nrified from the lupus mice, enhanced the expression of p-p38,\nwhereas anti-anti-Ribos.P inhibited the anti-Ribos.P effect on the\nmesangial cells, which confirm the specificity of the p38 activation\nby anti-Ribos.P Abs.\n\n4. Discussion\n\nIn the present study we demonstrated that recombinant\nRibos.P0 (38 kD) immunized NZBxW/F1 lupus prone mice, devel-\noped mouse anti-Ribos.P Abs, which did not target dsDNA and\nshare specificity with Sm antigen by 40%. Accelerated proteinuria\nwas detected in the Ribos.P immunized mice associated with renal\nhistopathology at week 24 of age revealed focal and diffuse pro-\nliferative damage in glomeruli with a diffuse peripheral deposition\ndemonstrated by immunofluorescence. Non-significant immuno-\nglobulin deposition was observed in the CFA adjuvant immunized\nmice or non-immunized mice at the same age of 24 weeks. The\ndirect nephritogenic properties of anti-Ribos.P was approved by a)\nrRibos.P immunized mice developed accelerated glomerulone-\nphritis. Mouse anti-Ribos.P Abs were detected in the kidneys from\nthe NZBxW/F1mice .b) Anti-Ribos.P mAb originated from rRibos.P0\nimmunized NZBxW/F1 did not bind dsDNA,share specificity with\nSm antigen. Anti-Ribos.P Abs from mouse and human origin acti-\nvate the phosphorylation of p38a and HSP27 MAPKs. c) C3H/Hen\nna\u00efve mice immunized with rRibos.P0 developed high levels of\ncirculating anti-Ribos.P, anti-dsDNA and anti-Sm/RNP Abs. The\nanti-Ribos.P Abs did not bind dsDNA but were cross reactive with\nSm antigen. The profile of circulating autoantibodies was associated\nwith sever glomerulonephritis that was illustrated by proteinuria\nand diffuse proliferative mesangial damage with diffuse peripheral\ndeposition. All C3H/Hen immunized mice with rRibos.P developed\nalopecia. Control mice did not develop either circulating autoanti-\nbodies nor nephritis or alopecia.\n\nThe MAPKs cascade is involved in many pathways of immune\nresponses, including cell proliferation, differentiation, and cell\ndeath. One of the three major groups of MAPKs in mammalian cells\nis the p38 MAPK. It is now well recognized that there are multiple\n\n\n\nFig. 5. Glomerulonephritis and alopecia in C3H/Hen na\u00efve mice immunized with rRibos.P. 5a: Immunoglobulin deposition in the kidneys of rRibos.P (A,B) or adjuvant\n(C) immunized mice. 5b: Alopecia on the face of rRibos.P immunized mouse in comparison to adjuvant injected mouse.\n\nD. Ben-Ami Shor et al. / Journal of Autoimmunity 54 (2014) 118e126124\nmechanisms of p38 activation. In the classical conserved cascade,\nMAP K 3 (MKK3), MKK4, and MKK6 activates p38 MAPK by a dual\nphosphorylation at the tripeptide motif Thr-Gly-Tyr [43,44]. Toll-\nlike receptors (TLRs) stimulate inflammatory pathways, ending in\nthe activation of nuclear factor (NF)-kB and activating protein-1\n(AP-1). p38 MAPK plays essential roles in mediating AP-1 activa-\ntion in TLR signaling [45]. It was suggested that MAPs are involved\nin the development of renal injury and have an important role in\nthe pathogenesis of glomerulonephritis. p38 MAPK is being acti-\nvated in normal human kidney and its activation is significantly\nincreased in class III and IV lupus glomerulonephritis and ANCA-\npositive pauci-immune crescentic glomerulonephritis. Activation\nof p38 MAPK in renal cells correlates with the degree of interstitial\ninflammation [46]. The expression of vascular cell adhesion\nmolecule-1 (VCAM-1) in human mesangial cells leads to recruit-\nment of leukocytes and monocytes adhesion to the glomerular\nmesangium. This is mediated, at least partially, by activation of p38\nMAPK [47]. Moreover, studies show that p38 MAP K inhibitors have\nfavorable effects by reducing glomerular infiltration and prolifera-\ntion [48,40]. Inhibition of p38 MAPK reduce glomerular macro-\nphage accumulation and crescent formation in vivo, and decrease\nanti-neutrophil cytoplasmic autoantibodies(ANCA)-activation of\nneutrophils in vitro [49]. The specific deposition and concentration\nof anti-Ribos.P at the site of tissue injury was previously demon-\nstrated by Reichlin\u2019s group, as they discovered a 30-fold enrich-\nment of anti-Ribos.P activity in the renal eluate from a patient with\nlupus nephritis [50]. In our study, human and mouse originated\nanti-Ribos.P activatedmesangial cells in-vitro, resulting in p38a and\nHSP27 phosphorylation. This finding confirms the pathogenic role\nof anti-Ribos.P autoantibodies.\n\nOur data contribute additional target epitope to the muliepitope\nnetwork of lupus related autoantibodies related to the mesangium\nin lupus. There are several autoantibodies which cross react with\ndsDNA such as actinin and annexin-II, which also activate mesan-\ngial cells via p38 [51,52].\n\nSLE has a wide range of clinical manifestations and lupus\nnephritis is a principal cause of death [1]. The currently used\nclassification of lupus nephritis includes 6 histologic classes as\ndiagnosed by kidney biopsy [3]. During exacerbation of lupus\nnephritis there is an increase in titer of anti dsDNA autoantibodies\nand formation of immune complex. Recurrent inflammation cause\neventually mesangial fibrosis and tubular atrophy [4].\n\nThe nephritogenic properties of anti-Ribos.P in the currenet\nstudy goes along with the previously suggested mechanisms\nwhich encompass the following: a) Anti-ribos.P Abs-mediated\ntissue injury. Ribos.P proteins are expressed as intracellular anti-\ngens and also as antigens that are displayed on the cell surfaces of\ndifferent tissues and numerous types of cells, including mesangial\ncells, astrocytes, neuroblastoma cells, hepatoma cells and fibro-\nblasts [32,36,37,39]. For example, anti-Ribos.P target and penetrate\nintracellular Jurkat T cells followed by apoptotic cell-death process\n[38]. Anti-Ribos.P penetrateinot HepG2 hepatocytes in-vitro and\ncause damage apolipoprotein B synthesis, resulting in tripling of\nthe amount of intra-cell cholesterol and lipid droplets (and\nthereby consistent with what is seen in various chronic liver dis-\neases) [32]. b) Anti-ribos.P Abs substantially inhibit the overall\nlevel of protein synthesis in-vitro, (as measured by methionine\nincorporation [35S]) [32,40]. c) Anti-Ribos.P Abs bind a neuronal\nsurface and are capable of inducing in vivo and in vitro apoptosis in\nneurons, following the flow of calcium into cells [41]. d) Anti-\nRibos.P may interfere with Th17 responses as a result of their\nactivation of the p38 MAPK, as it was shown that the p38a acted in\nDCs to regulate IL-6 and IL-27 and to initiate Th17 differentiation\nand autoimmune inflammation [42].\n\n\n\nFig. 6. In-vitro MAPKs analyses in primary mesangial cells culture upon exposure\nto anti-Ribos.P human or mouse mAb and controls IgG. 6a: MAPKs expression by\nmouse mesangial cells preexposed to human anti-Ribos.P or mouse anti-Ribos.P mAb\nand control human and mouse IgG1, for 1 h. 6b: Relative expression of p38a (real-time\nPCR) by mesangial cells preexposed to human anti-Ribos.P or mouse anti-Ribos.P mAb\nand control human and mouse IgG1, for 1 h. 6c: Immunoblot analysis of mesangial\ncells preincubated with anti-Ribo.P \ufffd anti-anti-Ribos.P and control IgG.\n\nD. Ben-Ami Shor et al. / Journal of Autoimmunity 54 (2014) 118e126 125\nFinally, the association of glomerulonephritis and elevated titers\nof anti-Ribos.P Abs in lupus patients was previously reported by\nseveral groups [22,23,27]. Our findings demonstrate for the first\ntime the direct nephritogenic properties of anti-Ribos.P autoanti-\nbodies and their role in the development of glomerulonephritis in\nexperimental model. In lupus As reported by Bonfa et al. Implica-\ntion to human: anti-Ribos.P can be considered as a biomarker for\nlupus nephritis in the sera.\nConflict of interest\n\nWe certify that there is no conflict of interest with any financial\norganization regarding the material discussed in the manuscript.\nReferences\n\n[1] Berden JH, Licht R, van Bruggen MC, Tax WJ. Role of nucleosomes for induction\nand glomerular binding of autoantibodies in lupus nephritis. Curr Opin\nNephrol Hypertens 1999;8:299e306.\n\n[2] Weening JJ, D\u2019Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al.\nThe classification of glomerulonephritis in systemic lupus erythematosus\nrevisited. Kidney Int 2004;65:521e30.\n\n[3] Yung S, Chan TM. Anti-DNA antibodies in the pathogenesis of lupus nephritis-\nthe emerging mechanisms. Autoimmun Rev 2008;7:317e21.\n\n[4] Koffler D, Schur PH, Kunkel HG. Immunological studies concerning the\nnephritis of systemic lupus erythematosus. J Exp Med 1967;126:607e24.\n\n[5] Gilliam BE, Ombrello AK, Burlingame RW, Pepmueller PH, Moore TL. Mea-\nsurement of autoantibodies in pediatric-onset systemic lupus erythematosus\nand their relationship with disease-associated manifestations. Semin Arthritis\nRheum 2012;41:840e8.\n\n[6] Renaudineau Y, Deocharan B, Jousse S, Renaudineau E, Putterman C,\nYouinou P. Anti-alpha-actinin antibodies: a new marker of lupus nephritis.\nAutoimmun Rev 2007;6:464e8.\n\n[7] Deocharan B, Qing X, Lichauco J, Putterman C. Alpha-actinin is a cross-\nreactive renal target for pathogenic anti-DNA antibodies. J Immunol\n2002;168:3072e8.\n\n[8] Kramers C, Hylkema MN, van Bruggen MC, van de Lagemaat R, Dijkman HB,\nAssmann KJ, et al. Anti-nucleosome antibodies complexed to nucleosomal\nantigens show anti-DNA reactivity and bind to rat glomerular basement\nmembrane in vivo. J Clin Invest 1994;94:568e77.\n\n[9] Deshmukh US, Bagavant H, Fu SM. Role of anti-DNA antibodies in the path-\nogenesis of lupus nephritis. Autoimmun Rev 2006;5:414e8.\n\n[10] Krishnan MR, Wang C, Marion TN. Anti-DNA autoantibodies initiate experi-\nmental lupus nephritis by binding directly to the glomerular basement\nmembrane in mice. Kidney Int 2012;82:184e92.\n\n[11] Sturgill BC, Carpenter RR. Antibody to ribosomes in systemic lupus erythe-\nmatosus. Arthritis Rheum 1965;8:213e8.\n\n[12] Towbin H, Ramjoue HP, Kuster H, Liverani D, Gordon J. Monoclonal antibodies\nagainst eucaryotic ribosomes. Use to characterize a ribosomal protein not\npreviously identified and antigenically related to the acidic phosphoproteins\nP1/P2. J Biol Chem 1982;257:12709e15.\n\n[13] Elkon K, Skelly S, Parnassa A, Moller W, Danho W, Weissbach H, et al. Iden-\ntification and chemical synthesis of a ribosomal protein antigenic determinant\nin systemic lupus erythematosus. Proc Natl Acad Sci U S A 1986;83:7419e23.\n\n[14] Arnett FC, Reveille JD, Moutsopoulos HM, Georgescu L, Elkon KB. Ribosomal P\nautoantibodies in systemic lupus erythematosus. Frequencies in different\nethnic groups and clinical and immunogenetic associations. Arthritis Rheum\n1996;39:1833e9.\n\n[15] Yoshio T, Masuyama J, Ikeda M, Tamai K, Hachiya T, Emori T, et al. Quantifi-\ncation of antiribosomal P0 protein antibodies by ELISA with recombinant P0\nfusion protein and their association with central nervous system disease in\nsystemic lupus erythematosus. J Rheumatol 1995;22:1681e7.\n\n[16] Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, et al. As-\nsociation between lupus psychosis and anti-ribosomal P protein antibodies.\nN Engl J Med 1987;317:265e71.\n\n[17] Katzav A, Solodeev I, Brodsky O, Chapman J, Pick CG, Blank M, et al. Induction\nof autoimmune depression in mice by anti-ribosomal P antibodies via the\nlimbic system. Arthritis Rheum 2007;56:938e48.\n\n[18] Mahler M, Kessenbrock K, Szmyrka M, Takasaki Y, Garcia-De La Torre I,\nShoenfeld Y, et al. International multicenter evaluation of autoantibodies to\nribosomal P proteins. Clin Vaccine Immunol 2006;13:77e83.\n\n[19] Hulsey M, Goldstein R, Scully L, Surbeck W, Reichlin M. Anti-ribosomal P\nantibodies in systemic lupus erythematosus: a case-control study correlating\nhepatic and renal disease. Clin Immunol Immunopathol 1995;74:252e6.\n\n[20] Carmona-Fernandes D, Santos MJ, Canhao H, Fonseca JE. Anti-ribosomal P\nprotein IgG autoantibodies in patients with systemic lupus erythematosus:\ndiagnostic performance and clinical profile. BMC Med 2013;11:98.\n\n[21] Reichlin M, Broyles TF, Hubscher O, James J, Lehman TA, Palermo R, et al.\nPrevalence of autoantibodies to ribosomal P proteins in juvenile-onset sys-\ntemic lupus erythematosus compared with the adult disease. Arthritis Rheum\n1999;42:69e75.\n\n[22] Meroni PL, de Bartolo G, Barcellini W, Riboldi PS, Basile R, Betterle C, et al.\nAnti-ribosomal ribonucleoprotein autoantibodies in systemic lupus erythe-\nmatosus. J Clin Immunol 1984;4:45e54.\n\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref1\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref1\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref1\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref1\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref2\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref2\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref2\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref2\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref3\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref3\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref3\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref4\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref4\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref4\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref5\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref5\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref5\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref5\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref5\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref6\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref6\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref6\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref6\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref7\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref7\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref7\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref7\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref8\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref8\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref8\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref8\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref8\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref9\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref9\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref9\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref10\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref10\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref10\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref10\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref11\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref11\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref11\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref12\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref12\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref12\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref12\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref12\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref13\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref13\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref13\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref13\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref14\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref14\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref14\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref14\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref14\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref15\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref15\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref15\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref15\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref15\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref16\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref16\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref16\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref16\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref17\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref17\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref17\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref17\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref18\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref18\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref18\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref18\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref19\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref19\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref19\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref19\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref20\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref20\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref20\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref21\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref21\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref21\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref21\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref21\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref22\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref22\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref22\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref22\n\n\nD. Ben-Ami Shor et al. / Journal of Autoimmunity 54 (2014) 118e126126\n[23] Chindalore V, Neas B, Reichlin M. The association between anti-ribosomal P\nantibodies and active nephritis in systemic lupus erythematosus. Clin\nImmunol Immunopathol 1998;87:292e6.\n\n[24] Martin AL, Reichlin M. Fluctuations of antibody to ribosomal P proteins\ncorrelate with appearance and remission of nephritis in SLE. Lupus 1996;5:\n22e9.\n\n[25] She QB, MaWY, Dong Z. Role of MAP kinases in UVB-induced phosphorylation\nof p53 at serine 20. Oncogene 2002;21:1580e9.\n\n[26] Takeda I, Iwadate H, Sugisaki K, Takahashi A, Nogae S, Kanno T, et al. Anti-\nribosomal P antibodies are associated with nephritis, vascular thrombosis and\nlymphocytopenia in patients with systemic lupus erythematosus. Fukushima J\nMed Sci 2005;51:11e8.\n\n[27] do Nascimento AP, Viana Vdos S, Testagrossa Lde A, Leon EP, Borba EF,\nBarros RT, et al. Antibodies to ribosomal P proteins: a potential serologic marker\nfor lupus membranous glomerulonephritis. Arthritis Rheum 2006;54:1568e72.\n\n[28] de Macedo PA, Borba EF, Viana Vdos S, Leon EP, Testagrossa Lde A, Barros RT,\net al. Antibodies to ribosomal P proteins in lupus nephritis: a surrogate\nmarker for a better renal survival? Autoimmun Rev 2011;10:126e30.\n\n[29] Bertolaccini ML, Murru V, Alba P, Khamashta MA. Lack of association of an-\ntibodies to ribosomal P proteins with lupus membranous glomerulonephritis:\ncomment on the article by Do Nascimento et al. Arthritis Rheum 2006;54:\n4025e6. author reply 6e7.\n\n[30] Quintana G, Coral-Alvarado P, Aroca G, Patarroyo PM, Chalem P, Iglesias-\nGamarra A, et al. Single anti-P ribosomal antibodies are not associated with\nlupus nephritis in patients suffering from active systemic lupus erythemato-\nsus. Autoimmun Rev 2010;9:750e5.\n\n[31] Massardo L, Burgos P, Martinez ME, Perez R, Calvo M, Barros J, et al. Anti-\nribosomal P protein antibodies in Chilean SLE patients: no association with\nrenal disease. Lupus 2002;11:379e83.\n\n[32] Koscec M, Koren E, Wolfson-Reichlin M, Fugate RD, Trieu E, Targoff IN, et al.\nAutoantibodies to ribosomal P proteins penetrate into live hepatocytes and\ncause cellular dysfunction in culture. J Immunol 1997;159:2033e41.\n\n[33] Blank M, Krause I, Ben-Bassat M, Shoenfeld Y. Induction of experimental anti-\nphospholipid syndrome associated with SLE following immunization with hu-\nman monoclonal pathogenic anti-DNA idiotype. J Autoimmun 1992;5:495e509.\n\n[34] Shoenfeld Y, Rauova L, Gilburd B, Kvapil F, Goldberg I, Kopolovic J, et al. Ef-\nficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic anti-\nbodies in the treatment of an experimental murine model of systemic lupus\nerythematosus. Int Immunol 2002;14:1303e11.\n\n[35] Blank M, Baraam L, Eisenstein M, Fridkin M, Dardik R, Heldman Y, et al. Beta2-\nGlycoprotein-I based peptide regulate endothelial-cells tissue-factor expres-\nsion via negative regulation of pGSK3beta expression and reduces experi-\nmental-antiphospholipid-syndrome. J Autoimmun 2011;37:8e17.\n\n[36] Koren E, Reichlin MW, Koscec M, Fugate RD, Reichlin M. Autoantibodies to the\nribosomal P proteins react with a plasma membrane-related target on human\ncells. J Clin Invest 1992;89:1236e41.\n[37] Gerli R, Caponi L. Anti-ribosomal P protein antibodies. Autoimmunity\n2005;38:85e92.\n\n[38] Sun KH, Tang SJ, Lin ML, Wang YS, Sun GH, Liu WT. Monoclonal antibodies\nagainst human ribosomal P proteins penetrate into living cells and cause\napoptosis of Jurkat T cells in culture. Rheumatology (Oxford) 2001;40:750e6.\n\n[39] Reichlin M. Cellular dysfunction induced by penetration of autoantibodies\ninto living cells: cellular damage and dysfunction mediated by antibodies to\ndsDNA and ribosomal P proteins. J Autoimmun 1998;11:557e61.\n\n[40] Stacey DW, Skelly S, Watson T, Elkon K, Weissbach H, Brot N. The inhibition of\nprotein synthesis by IgG containing anti-ribosome P autoantibodies from sys-\ntemic lupus erythematosus patients. Arch BiochemBiophys 1988;267:398e403.\n\n[41] Matus S, Burgos PV, Bravo-Zehnder M, Kraft R, Porras OH, Farias P, et al.\nAntiribosomal-P autoantibodies from psychiatric lupus target a novel\nneuronal surface protein causing calcium influx and apoptosis. J Exp Med\n2007;204:3221e34.\n\n[42] Huang G, Wang Y, Vogel P, Kanneganti TD, Otsu K, Chi H. Signaling via the\nkinase p38alpha programs dendritic cells to drive TH17 differentiation and\nautoimmune inflammation. Nat Immunol 2012;13:152e61.\n\n[43] Derijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ, et al. Independent\nhuman MAP-kinase signal transduction pathways defined by MEK and MKK\nisoforms. Science 1995;267:682e5.\n\n[44] Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev\nImmunol 2002;20:55e72.\n\n[45] Kawai T, Akira S. TLR signaling. Cell Death Differ 2006;13:816e25.\n[46] Stambe C, Nikolic-Paterson DJ, Hill PA, Dowling J, Atkins RC. p38 Mitogen-\n\nactivated protein kinase activation and cell localization in human glomeru-\nlonephritis: correlation with renal injury. J Am Soc Nephrol 2004;15:326e36.\n\n[47] Lee IT, Shih RH, Lin CC, Chen JT, Yang CM. Role of TLR4/NADPH oxidase/ROS-\nactivated p38 MAPK in VCAM-1 expression induced by lipopolysaccharide in\nhuman renal mesangial cells. Cell Commun Signal 2012;10:33.\n\n[48] Sheryanna A, Bhangal G, McDaid J, Smith J, Manning A, Foxwell BM, et al.\nInhibition of p38 mitogen-activated protein kinase is effective in the treat-\nment of experimental crescentic glomerulonephritis and suppresses mono-\ncyte chemoattractant protein-1 but not IL-1beta or IL-6. J Am Soc Nephrol\n2007;18:1167e79.\n\n[49] van der Veen BS, Chen M, Muller R, van Timmeren MM, Petersen AH, Lee PA,\net al. Effects of p38 mitogen-activated protein kinase inhibition on anti-\nneutrophil cytoplasmic autoantibody pathogenicity in vitro and in vivo. Ann\nRheum Dis 2011;70:356e65.\n\n[50] Reichlin M, Wolfson-Reichlin M. Evidence for the participation of anti-\nribosomal P antibodies in lupus nephritis. Arthritis Rheum 1999;42:2728e9.\n\n[51] Deocharan B, Zhou Z, Antar K, Siconolfi-Baez L, Angeletti RH, Hardin J, et al.\nAlpha-actinin immunization elicits anti-chromatin autoimmunity in non-\nautoimmune mice. J Immunol 2007;15(179):1313e21.\n\n[52] Yung S, Cheung KF, Zhang Q, Chan TM. Anti-dsDNA antibodies bind to\nmesangial annexin II in lupus nephritis. J Am Soc Nephrol 2010;21:1912e27.\n\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref23\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref23\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref23\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref23\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref24\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref24\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref24\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref24\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref25\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref25\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref25\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref26\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref26\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref26\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref26\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref26\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref27\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref27\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref27\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref27\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref28\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref28\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref28\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref28\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref29\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref29\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref29\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref29\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref29\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref29\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref30\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref30\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref30\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref30\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref30\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref31\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref31\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref31\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref31\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref32\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref32\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref32\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref32\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref33\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref33\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref33\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref33\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref34\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref34\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref34\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref34\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref34\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref35\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref35\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref35\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref35\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref35\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref36\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref36\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref36\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref36\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref37\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref37\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref37\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref38\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref38\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref38\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref38\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref39\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref39\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref39\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref39\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref40\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref40\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref40\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref40\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref41\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref41\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref41\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref41\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref41\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref42\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref42\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref42\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref42\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref43\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref43\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref43\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref43\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref44\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref44\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref44\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref45\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref45\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref46\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref46\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref46\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref46\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref47\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref47\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref47\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref48\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref48\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref48\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref48\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref48\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref48\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref49\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref49\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref49\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref49\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref49\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref50\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref50\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref50\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref51\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref51\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref51\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref51\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref52\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref52\nhttp://refhub.elsevier.com/S0896-8411(14)00064-X/sref52\n\n\nUpdate\n\nJournal of Autoimmunity\nVolume 67, Issue , February 2016, Page 111\n\n https://doi.org/10.1016/j.jaut.2015.12.001DOI:\n\n https://doi.org/10.1016/j.jaut.2015.12.001\n\n\nJournal of Autoimmunity 67 (2016) 111\nContents lists available at ScienceDirect\nJournal of Autoimmunity\n\njournal homepage: www.elsevier .com/locate/ jaut imm\nCorrigendum\nCorrigendum to \u201cAnti-ribosomal-P antibodies accelerate lupus\nglomerulonephritis and induce lupus nephritis in na\u00efve mice\u201d\n[J. Autoimmun. 54C (2014) 118e126]\n\nDana Ben-Ami Shor a, 1, Miri Blank a, 1, Sandra Reuter b, Torsten Matthias b, Inbal Beiglass a,\nAlexander Volkov c, Iris Barshack c, Yehuda Shoenfeld a, *\n\na The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Israel\nb AESKU.KIPP Institute, Mikroforum Ring, Wendelsheim, Germany\nc Institute of Pathology, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Israel\nUnfortunately the following error was made for Fig. 3B in the original article:\nThere were 2 negative pictures, no immunoglobulin deposits in the kidney sections originated from the lupus mice (NZB \ufffd W/F1) at an\n\nearly stage and in the adjuvant injected lupus prone mice.\nThe mistake was technical; the author had two negative pictures from the 2 groups. The author chosed the negative pictures from each\n\ngroup but uploaded twice the negative picture from the group of adjuvant injected mice.\nTherefore, please find the corrected negative picture below.\n\nThe authors wish to apologise for any inconvenience caused.\nDOI of original article: http://dx.doi.org/10.1016/j.jaut.2014.02.013.\n* Corresponding author. Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer 52621, Israel.\n\nE-mail addresses: mblank@post.tau.ac.il (M. Blank), shoenfel@post.tau.ac.il (Y. Shoenfeld).\n1 The first two authors equally contributed to the paper.\n\nhttp://dx.doi.org/10.1016/j.jaut.2015.12.001\n0896-8411/\u00a9 2015 Elsevier Ltd. All rights reserved.\n\nhttp://dx.doi.org/10.1016/j.jaut.2014.02.013\nmailto:mblank@post.tau.ac.il\nmailto:shoenfel@post.tau.ac.il\nhttp://crossmark.crossref.org/dialog/?doi=10.1016/j.jaut.2015.12.001&domain=pdf\nwww.sciencedirect.com/science/journal/08968411\nwww.elsevier.com/locate/jautimm\nhttp://dx.doi.org/10.1016/j.jaut.2015.12.001\nhttp://dx.doi.org/10.1016/j.jaut.2015.12.001\n\n\tAnti-ribosomal-P antibodies accelerate lupus glomerulonephritis and induce lupus nephritis in na\u00efve mice\n\t1 Introduction\n\t2 Materials and methods\n\t2.1 Antibodies\n\t2.2 Synthetic peptides\n\t2.3 Immunization\n\t2.4 Detection of autoantibodies in mice sera\n\t2.5 Evaluation of renal disease\n\t2.6 Immunoglobulin elution from the kidneys\n\t2.7 Preparation of primary mouse mesangial cells (MCs)\n\t2.8 MCs Treatments, lysate preparation, immunoblotting and real-time-PCR\n\n\t3 Results\n\t3.1 rRibos.P0 NZBxW/F1 immunized mice developed accelerated glomerulonephritis\n\t3.2 Na\u00efve mice immunized with rRibos.P0, developed glomerulonephritis and experimental lupus\n\t3.3 Anti-Ribos.P activate p38 MAPK in mesangial cells in-vitro\n\n\t4 Discussion\n\tConflict of interest\n\tReferences\n\n\tUpdate\n\tCorrigendum to \u201cAnti-ribosomal-P antibodies accelerate lupus glomerulonephritis and induce lupus nephritis in na\u00efve mice\u201d [ ...\n\n\n",
  "status": 200
}